Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 13/20 | 0.62 |
| ▸ | FAAH | O00519 | 8/20 | 0.62 |
| ▸ | CES1 | P23141 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3955586 | 0.96 | DAGLA (0.60) | DAGLAFAAHCES1ALDH1A1MAPT | |
| SCHEMBL4050534 | 0.91 | DAGLA (0.55) | DAGLAFAAHCES1ALDH1A1MAPT | |
| SCHEMBL6062417 | 0.84 | DAGLA (0.67) | DAGLAFAAHCES1XDH | |
| SCHEMBL4046625 | 0.83 | DAGLA (0.62) | DAGLAFAAHCES1 | |
| SCHEMBL5522120 | 0.83 | DAGLA (0.62) | DAGLAFAAHCES1XDH | |
| SCHEMBL6063622 | 0.79 | DAGLA (0.60) | DAGLAFAAHCES1ALDH1A1KMT2A | |
| SCHEMBL4051007 | 0.79 | DAGLA (0.44) | DAGLAFAAHCES1MAPTKMT2A | |
| SCHEMBL4048936 | 0.79 | DAGLA (0.44) | DAGLAFAAHCES1ALDH1A1MAPT | |
| SCHEMBL4048199 | 0.79 | DAGLA (0.60) | DAGLAFAAHCES1XDH | |
| SCHEMBL3962620 | 0.79 | FAAH (0.85) | DAGLAFAAHCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1744755-B1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2012-12-05 | — | — | EP | claimed |
| EP-1744755-A4 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2009-07-15 | — | — | EP | claimed |
| JP-2007535568-A | — | — | 2007-12-06 | — | — | JP | claimed |
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | IRM LLC (BM) | 2007-10-04 | — | — | US | claimed |
| CN-1976710-A | Compounds and compositions as cathepsin S inhibitors | IRM LLC (BM) | 2007-06-06 | — | — | CN | claimed |
| EP-1744755-A2 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM, LLC (BM) | 2007-01-24 | — | — | EP | claimed |
| WO-2005107464-A2 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2005-11-17 | — | — | WO | claimed |
| EP-1744755-B1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2012-12-05 | — | — | EP | disclosed |
| EP-1744755-A4 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2009-07-15 | — | — | EP | disclosed |
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | IRM LLC (BM) | 2007-10-04 | — | — | US | disclosed |
| CN-1976710-A | Compounds and compositions as cathepsin S inhibitors | IRM LLC (BM) | 2007-06-06 | — | — | CN | disclosed |
| EP-1744755-A2 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM, LLC (BM) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005107464-A2 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | CTSS, CTSB, CTSF | DAGLA 2256/4885FAAH 519/4885CES1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.